Debra K. Liebert

Ms. Liebert has served as a member of Milestone’s board of directors since June 2015. Currently, Ms. Liebert is a consultant to the biopharma industry. Most recently, she served as Managing Director at Domain Associates, LLC where she contributed to new company creation, and portfolio management. She was a founder of Calixa Therapeutics (sold to Cubist), Merada Therapeutics, Nanothera Corporation, and Sonexa Therapeutics. She actively participated as an observer serving Tobira Therapeutics (sold to Allergan), Atara Biotherapeutics, and the Sonexa boards of directors. Prior to Domain, Ms. Liebert’s extensive drug development and biopharmaceutical experience includes positions as Executive Director of New Product Management for CancerVax Corporation where she designed and implemented development plans for pipeline product candidates, Vice President, Corporate Development at Atairgin Technologies, where she led product and business development, and Vice President, Corporate Development at Trega Biosciences, where she led corporate development transactions including the merger of the company. Ms. Liebert also directed clinical research programs for Gensia, the Institute for Biological Research and Development, and Merck & Co.

Ms. Liebert received her BS in Chemistry from Clarion University, her MS in Pharmacology/Toxicology from Duquesne University, and her MBA from UCLA.